ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2229 • ACR Convergence 2023

    Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies

    Laura Coates1, Iain McInnes2, Sibel Aydin3, Mitsumasa Kishimoto4, Philip J. Mease5, May Shawi6, Miriam Zimmermann7, Emmanouil Rampakakis8, Frederic Lavie9 and Dennis McGonagle10, 1University of Oxford, Oxford, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, 4Kyorin University School of Medicine, Yokohoma, Japan, 5Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 6Immunology, Janssen Research & Development, LLC, Titusville, NJ, 7Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, 8McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, 9The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, 10Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

    Background/Purpose: In patients with mono/oligoarticular psoriatic arthritis (PsA), swelling or tenderness of specific joints can be associated with poorer patient-reported outcomes (PROs) and physician global…
  • Abstract Number: 2228 • ACR Convergence 2023

    Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment

    William R Tillett1, Laura Coates2, marijn vis3, Enrique Soriano4, Joseph F. Merola5, Miriam Zimmermann6, May Shawi7, Mohamed Sharaf8, Peter Nash9 and Philip Helliwell10, 1Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3Erasmus Medical Center, Rotterdam, Netherlands, 4Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, 7Immunology, Janssen Research & Development, LLC, Titusville, NJ, 8Immunology, Janssen MEA, Dubai, United Arab Emirates, 9School of Medicine, Griffith University, Brisbane, Australia, 10University of Leeds, Leeds, United Kingdom

    Background/Purpose: Guselkumab (GUS), a fully human IL-23p19 subunit inhibitor, was shown to reduce mean changes in radiographic progression vs placebo (PBO) by week (W)24 and…
  • Abstract Number: 1738 • ACR Convergence 2023

    Identification of Homeostatic and Inflammatory Synovial Fibroblast Signatures in Synovial Tissue Biopsies of Healthy Controls and Patients with Rheumatoid Arthritis

    Brianne Barker1, Órla Tynan2, Conor Smith3, Dumitru Anton4, Carl Orr5, Mary Canavan6, Douglas Veale7 and Ursula Fearon8, 1Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Rheumatic and Arthritic Diseases, St Vincent's University Hospital, University College Dublin, Dublin, Ireland, 2Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 3Translational Immunology, Trinity Biomedical Sciences Institute, Dublin, Ireland, 4Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 5EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 6Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, 7St.Vincent's University Hosp, Dublin, Ireland, 8Trinity College Dublin, Dublin, Ireland

    Background/Purpose: Recent literature has identified different synovial fibroblast (FLS) populations within RA synovium with distinct inflammatory profiles. Despite current advances in classifying heterogeneity of FLS…
  • Abstract Number: 1742 • ACR Convergence 2023

    Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA

    Rachna Talluri1, Sudeshna Sen2, Timothy Wilson3, Adam Savage4, Mark Gillespie4, Tom Bumol4, Marie Feser1, Jill Norri5, Michael Holer1, kevin Deane1, Paul Thompson2 and Kristen Demoruelle1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Massachusetts Chan Medical School, Worcester, MA, 3Thomas Jefferson University, Philadelphia, PA, 4Allen Institute for Immunology, Seattle, WA, 5Colorado School of Public Health, Denver, CO

    Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
  • Abstract Number: 1702 • ACR Convergence 2023

    Outcomes in Systemic Sclerosis Patients Treated with Rituximab and Mycophenolate Mofetil Combination Therapy Compared to Autologous Hematological Stem Cell Transplantation

    shiri keret1, Lisa Kaly2, Aniela Shouval2, Tsila Zuckerman3, Israel Henig4, Abid Awisat5, Itzhak Rosner6, Michel Rozenbaum2, Nina Boulman2, Yair Molad7, ariela Dortort Lazar8, Gleb Slobodin2 and Doron Rimar2, 1Bnai Zion, Atlit, Israel, 2Bnai Zion Medical Center, Haifa, Israel, 3Hematology department, Rambam Medical Center, Haifa, Israel, 4Stem cell transplantation unit, Hematology department, Rambam Medical Center, Haifa, Israel, 5Bney-Zion Medical Center, Baqa Elgharbiya, Israel, 6Bnai Zion Medical Center/Technion, Haifa, Israel, 7Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, 8Rabin Medical Center and Tel Aviv university, Tel Aviv, Israel

    Background/Purpose: Autologous hematological stem cell transplantation (AHSCT) is a grade A therapy for early diffuse progressive systemic sclerosis (SSc), that has been validated in three…
  • Abstract Number: 2227 • ACR Convergence 2023

    The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration

    Zohra Faizy Ahmadzay1, Stylianos Georgiadis2, Marion Pons2, Merete Hetland2, Bente Glintborg3, Jette Heberg2, Sara Nysom Christiansen2, Simon Horskjær Rasmussen2, Anne Gitte Loft4, Isabel Castrejon5, Lucia Otero-Valera6, Jakub Zavada7, Karel Pavelka8, Heikki Relas9, Laura Kuusalo10, Burkhard Moeller11, Michael Nissen12, Ziga Rotar13, Katja Perdan Pirkmajer14, Daniela Santos Oliveira15, Ana Rita Cruz-Machado16, Brigitte Michelsen17, Eirik Kristianslund18, Bjorn Gudbjornsson19, Gerdur Maria Grondal20, Karin Laas21, Pasoon Hellamand22, Ismail Sari23, Daniela Di Giuseppe24, Mikkel Østergaard25 and Lykke Ørnbjerg2, 1Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark, 2Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, 3Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, 4Aarhus University, Horsens, Denmark, 5Hospital General Universitario Gregorio Marañón, Madrid, Spain, 6Spanish Society of Rheumatology, Madrid, Spain, 7Institute of Rheumatology; Charles University, Prague, Czech Republic, 8Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, 9Helsinki University Hospital, Helsinki, Finland, 10Division of Internal Medicine, Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, 11Inselspital - University Hospital Bern, Bern, Switzerland, 12Geneva University Hospitals, Geneva, Switzerland, 13University Medical Centre Ljubljana, Ljubljana, Slovenia, 14Department of Rheumatology, University Medical Centre LJubljana, Ljubljana, Slovenia, 15Department of Medicine, Faculty of Medicine, University of Porto, Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, 16Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHULN, Academic Medical Center and ERN-ReCONNET; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa; Reuma.pt Sociedade Portuuesa de Reumatologia, Lisbon, Portugal, 17Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, 18Diakonhjemmet Hospital, Oslo, Norway, 19Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, 20Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, 21Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, 22Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 23Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey, 24Karolinska Institutet, Stockholm, Sweden, 25Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Smoking has been associated with higher disease activity, poorer treatment response, and drug retention rate among psoriatic arthritis (PsA) patients treated with Tumor Necrosis…
  • Abstract Number: 2224 • ACR Convergence 2023

    Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes

    FERNANDO MONTERO1, Laura Berbel Arcobé2, Karen Carpio Astudillo1, Jose Maria Bellón3 and Xavier Juanola Roura4, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2H.U. Bellvitge, Barcelona, Spain, 3Gregorio Marañón Health Research Institute, Madrid, Spain, 4Hospital Universitari de Bellvitge, Barcelona, Spain

    Background/Purpose: The term "Difficult-to-Treat" (D2T) defines those patients who remain active despite having undergone various treatments within the established recommendations. This concept is defined by…
  • Abstract Number: 1746 • ACR Convergence 2023

    Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies

    Tineke van Wesemael1, Anna Svärd2, Annemarie Dorjee1, Thomas Huizinga1, René Toes1 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Centre for Clinical Research Dalarna, Uppsala, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by autoantibodies to anti-modified protein autoantibodies (AMPAs) like anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). Smoking is…
  • Abstract Number: 2223 • ACR Convergence 2023

    Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study

    Srujana Budumuru, Rohini Handa, Sundeep Kumar Upadhyaya, Sirinder Jit Gupta, Meera H Shah, Meera P Shah and Anushka Aggarwal, Indraprastha Apollo Hospital, Delhi, India

    Background/Purpose: Sleep problems are prevalent in 30-70% of patients with axial Spondyloarthritis (SpA), negatively impacting their quality of life. Poor sleep quality in these patients…
  • Abstract Number: 1607 • ACR Convergence 2023

    Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus

    Eduardo Gomez-Banuelos1, Alessandra Ida Celia2, Maria Isabel Trejo Zambrano3, Merlin Paz3, Erika Darrah3, Daniel Goldman4, Michelle Petri4 and Felipe Andrade3, 1The Johns Hopkins University, Baltimore, MD, 2John Hopkins University of Medicine, Rome, Italy, 3Johns Hopkins University, Baltimore, MD, 4Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
  • Abstract Number: 1723 • ACR Convergence 2023

    3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity

    Brendan Allen1, Sabrina Fechtner2, Meagan Chriswell3, Widian Jubair1, M. Aaron Vrolijk1, V. Michael Holers4 and kristine Kuhn1, 1University of Colorado School of Medicine, Aurora, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of Colorado Anschutz SOM, Denver, CO, 4University of Colorado, Denver, CO

    Background/Purpose: Both human and animal studies associate specific microbiota and microbial metabolic pathways with the development of RA and autoimmune arthritis, thereby providing a novel…
  • Abstract Number: 1610 • ACR Convergence 2023

    Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial

    Michael Gendreau1, Andrea Chadwick2, Lance McCracken3, David Williams4, Daniel Clauw5, Juan Luciano6, Yifei Dai7, Nicolette Vega8, Zunera Ghalib8, Kristen Guthrie8, Allison Kraus8, Michael Rosenbluth8, Jennifer Zomnir9, Dana Reddy10 and Lesley arnold11, 1Gendreau Consulting, LLC, Poway, CA, 2Department of Anesthesiology, Pain, and Perioperative Medicine, University of Kansas School of Medicine, Kansas City, KS, 3Department of Psychology, Uppsala University, Uppsala, Sweden, 4Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, 5Department of Anesthesiology, University of Michigan, Ann Arbor, MI, 6Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona, Barcelona, Spain, 7Swing Therapeutics, Gainesville, FL, 8Swing Therapeutics, San Francisco, CA, 9DelRicht Resesarch, Mckinney, TX, 10Curavit, Scarsdale, NY, 11Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH

    Background/Purpose: Acceptance and Commitment Therapy (ACT), a form of guideline-recommended Cognitive Behavioral Therapy (CBT), has been empirically validated as a non-drug treatment for fibromyalgia (FM).…
  • Abstract Number: 1611 • ACR Convergence 2023

    Mitochondrial Structural Alterations in Fibromyalgia – A Pilot Electron Microscopy Study

    Linoy Israel1, Victoria Furer2, Atan Gross1 and Jacob Ablin2, 1Weizmann Institute of Science, Rehovot, Israel, 2Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Background/Purpose: Fibromyalgia (FM) is among the most common chronic pain conditions, clinically characterized by widespread pain and fatigue. FM pathogenesis remains unknown, leading to challenges…
  • Abstract Number: 1623 • ACR Convergence 2023

    Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement, Antibody Pattern and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the Juvenile Scleroderma Inception Cohort

    Ivan Foeldvari1, Jens Klotsche2, Kathryn Torok3, Ozgur Kasapcopur4, Amra Adrovic5, Brian Feldman6, FLAVIO SZTAJNBOK7, Maria Teresa TErreri8, Ana Sakamoto9, Sindhu Johnson10, Jordi Anton11, Valda Stanevica12, Raju Khubchandani13, Dieneke Schonenberg-Meinema14, Eslam Al-Abadi15, Ekaterina Alexeeva16, Maria Katsikas17, Sujata Sawhney18, Vanessa Smith19, Simone Appenzeller20, Tadey Avcin21, Mikhail Kostik22, Thomas Lehman23, Hana Malcova24, Edoardo Marrani25, Clare Pain26, Natalia Vasquez-Canizares27, Patricia Costa Reis28, Mahesh Janarthanan29, Maria Jose Santos30, Sima Abu Alsaoud31, Christina Battagliotti32, Lillemor Berntson33, blanca e r bica34, Juergen Brunner35, Daniela Kaiser36, Dragana Lazarevic37, Kirsten Minden38, Farzana Nuruzzaman39, Siri Opsahl Hetlevik40, Yosef Uziel41 and Nicola Helmus42, 1Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, 2German Rheumatism Research Center, Berlin, Germany, 3University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Department of Pediatric Rheumatology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey, 5Istanbul University - Cerrahpasa, Istanbul, Turkey, 6The Hospital for Sick Children, Toronto, ON, Canada, 7UFRJ/UERJ, São Paulo, Brazil, 8UNIFESP, São Paulo, Brazil, 9Federal University of São Paulo (UNIFESP), São Paulo, Brazil, 10Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 11Hospital Sant Joan de Déu, Pediatric Rheumatology Department, Universitat de Barcelona, Barcelona, Spain, 12Children's Clinical University Hospital, Zemgales priekšpilseta, Riga, Latvia, 13SRCC Childrens Hospital, Mumbai, India, 14Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, 15Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom, 16Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, 17Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, 18Sir Ganga Ram Hospital, Uttar Pradesh, India, 19Ghent University Hospital, Gent, Belgium, 20UNICAMP, Campinas, Brazil, 21University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia, 22Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 23Hospital for Special Surgery, New York, NY, 24Motol University Hospital, Prague, Czech Republic, 25University of Florence, Firenze, Italy, 26Alder Hey NHS Trust, Liverpool, United Kingdom, 27Children’s Hospital at Montefiore, Bronx, NY, 28Hospital de Santa Maria, Lisbon, Portugal, 29SRI RAMACHANDRA INSTITUTE OF HIGHER EDUCATION AND RESEARCH, Chennai, India, 30Hospital Garcia de Orta, Almada, Lisboa, Portugal, 31Caritas baby Hospital, East Jerusalem, Israel, 32Hospital de Niños Dr Orlando Alassia, Santa Fe, Argentina, 33Dept. of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden, 34Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 35Medical University Innsbruck; Department of Pediatrics, Pediatric Rheumatology, Innsbruck, Austria, 36Children's Hospital Lucerne, Lucerne, Switzerland, 37Dept of Pediatric Rheumatology and Immunology Clinical Center Nis, Faculty of Medicine, University of Niš, Nis, Serbia, 38Charité University Medicine and German Rheumatism Research Center Berlin, Berlin, Germany, 39Stony Brook Children's Hospital, Stony Brook, NY, 40Oslo University Hospital, Oslo, Norway, 41Pediatric Rheumatology Unit, Meir Medical Center, Kfar Saba, Sackler School of Medicine, Tel Aviv University, Kfar Saba, Israel, 42Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany

    Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. In adult patients there are significant differences between…
  • Abstract Number: 1202 • ACR Convergence 2023

    Goal Concordant Patient-clinician Dyads Have Higher Odds of Communication Around Rheumatoid Arthritis Goals

    Jennifer Barton1, Danielle ZuZero2, Diego Molina Ochoa3, Rachel Matsumoto4 and Edward Yelin5, 1VA Portland Health Care System/OHSU, Portland, OR, 2National University of Natural Medicine, Portland, OR, 3University of Maryland School of Medicine, Baltimore, MD, 4VA Portland Health Care System, Portland, OR, 5University of California San Francisco, San Francisco, CA

    Background/Purpose: Goal concordance between patients with chronic disease and their clinicians is linked to improved outcomes, however, less is known about goal concordance and goal…
  • « Previous Page
  • 1
  • …
  • 442
  • 443
  • 444
  • 445
  • 446
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology